Open access
Aug 2026
Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.
Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a non-invasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed. We conducted a multicenter, retrospective study of patients with LBCL assessed in rea...
Patrick Gould, D. Coskey, Xin Ma et al.
· Haematologica · 0 citations